Results 101 to 110 of about 12,617 (217)

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome [PDF]

, 2016
Background: The role of complement in the atypical form of hemolytic uremic syndrome (aHUS) has been investigated extensively in recent years. As the HUS-associated bacteria Shiga-toxin-producing Escherichia coli (STEC) can evade the complement system ...
Bakker, J.A. (Jaap), Bouts, A.H. (Antonia), Dorresteijn, E.M. (Eiske), Goertz, J. (Joop), Gracchi, V. (Valentina), Heuvel, L.P. (Lambert) van den, Jeronimus-Klaasen, A. (Annelies), Kar, N.C. (Nicole) van de, Keijzer-Veen, M.G. (Mandy), Roos, A. (Anja), van der Molen, R.G. (Renate G.), van der Velden, T.J.A.M. (Thea J. A. M.), van Wijk, J.A.E. (Joanna A. E.), Volokhina, E.B. (Elena), Westra, D.F.   +14 more
core   +7 more sources

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

Hematology Reports, 2018
Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage.
Serife Solmaz Medeni, Sinem Namdaroglu, Tugba Cetintepe, Can Ozlu, Funda Tasli, Zehra Hilal Adibelli, Oktay Bilgir, Erhan Tatar   +7 more
doaj   +1 more source

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso [PDF]

, 2016
Trobareu una actualització (2015) d'aquest document a: http://hdl.handle.net/2445/99427Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the ...
Arias, Manuel, Ariceta, Gema, Blasco, Miguel, Campistol Plana, Josep M., Espinosa, Mario, Grinyó Boira, Josep M., Praga, Manuel, Rodríguez de Córdoba, Santiago, Torra, Roser, Vilalta, Ramon (Vilalta Casas)   +9 more
core   +1 more source

Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. [PDF]

, 2014
The presence of circulating autoantibodies, primarily to complement factor H antibodies (CFH-Abs) in plasma characterizes the autoimmune form of atypical hemolytic uremic syndrome (aHUS).
Giner, T., Hofer, J., Józsi, Mihály
core   +1 more source

Postoperative atypical hemolytic uremic syndrome in nontransplant setting: A case report with review of literature

Global Journal of Transfusion Medicine, 2018
Atypical hemolytic uremic syndrome (aHUS) is a clinical diagnosis characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. Postoperative aHUS in nontransplant patients is a rare entity.
Anil Khetarpal, Vidhi Gupta, Urvershi Kotwal   +2 more
doaj   +1 more source

Atypical hemolytic-uremic syndrome, manifesting without thrombocytopenia (clinical case)

Известия высших учебных заведений. Поволжский регион: Медицинские науки
Background. Atypical hemolytic uremic syndrome is an ultra-rare (orphan) disease from the group of thrombotic microangiopathies of progressive course, which is caused by uncontrolled activation of the alternative complement pathway of hereditary or ...
A.A. Dyachkova, A.N. Anokhin, M.A. Shlykova, I.S. Kiseleva   +3 more
doaj   +1 more source

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. [PDF]

, 2014
BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized ...
A Szilagyi, Aspazija Sofijanova, Attila Szabó, C Loirat, CM Legendre, D Kavanagh, D Magen, F Fakhouri, F Fakhouri, G Ariceta, G Ariceta, György Reusz, J Caprioli, J Zuber, J Zuber, JM Campistol, Klaus Arbeiter, Krisztina Rusai, Lilla Szeifert, LM Geerdink, M Christmann, M Heurich, M Jozsi, M Lemaire, M Reti, MA Abrera-Abeleda, MA Dragon-Durey, Miklós Szabó, N Besbas, Nóra Szarvas, RA Gruppo, RL Ruebner, S Jung, Thomas Müller, Valbona Nushi-Stavileci, Velibor Tasic, Z Prohaszka, Zoltán Prohászka, Zoran Gucev, Ágnes Szilágyi   +39 more
core   +1 more source

Managing atypical hemolytic uremic syndrome: chapter 2 [PDF]

Kidney International, 2015
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment.
openaire   +2 more sources

Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. [PDF]

, 2014
The alternative pathway of complement is implicated in the pathogenesis of several renal diseases, such as atypical hemolytic uremic syndrome, dense deposit disease and other forms of C3 glomerulopathy.
Józsi, Mihály, Lopez-Trascasa, M., Nozal, P., Prohászka, Zoltán, Reuter, S., Sanchez-Corral, P., Uzonyi, Barbara   +6 more
core   +1 more source

Concurrent Atypical Hemolytic Uremic Syndrome and Autoimmune Hemolytic Anemia: a case report

Caspian Journal of Pediatrics, 2018
Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening and scarce disorder characterized by acute renal failure and disease, non-immune microangiopathic hemolytic anemia and thrombocytopenia, leading to end-stage renal failure or ...
Sayed Yousef Mojtahedi, Mohammad Kaji Yazdi   +1 more
doaj